SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.940
-0.046 (-4.65%)
Apr 29, 2026, 1:56 PM EDT - Market open
SCYNEXIS Employees
SCYNEXIS had 18 employees as of December 31, 2025. The number of employees decreased by 10 or -35.71% compared to the previous year.
Employees
18
Change (1Y)
-10
Growth (1Y)
-35.71%
Revenue / Employee
$1,144,500
Profits / Employee
-$478,278
Market Cap
74.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Alpha Teknova | 158 |
| Cumberland Pharmaceuticals | 93 |
| Journey Medical | 58 |
| Assertio Holdings | 53 |
| Cardiol Therapeutics | 18 |
| Incannex Healthcare | 12 |
SCYX News
- 4 weeks ago - SCYNEXIS Transcript: M&A announcement - Transcripts
- 4 weeks ago - Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
- 4 weeks ago - SCYNEXIS Announces $40.0 Million Private Placement - GlobeNewsWire
- 4 weeks ago - SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 7 weeks ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 4 months ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire